Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Eli Lilly and Company (LLY) is running a late-stage study of retatrutide, a weekly shot aimed at helping people with obesity or overweight lose weight. The trial, officially titled “A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight,” focuses on weight loss results and safety, a key area for future revenue growth.
The treatment being tested is retatrutide (also called LY3437943), a drug given as a subcutaneous injection once a week. It is compared with a placebo shot to see how well it reduces body weight and how safe it is over time in people who do not have type 2 diabetes.
The study is a randomized trial, so participants are split into groups by chance to receive either one of two retatrutide doses or a placebo. It is double-blind and placebo-controlled, meaning neither patients nor doctors know who gets the real drug, and the main goal is to test retatrutide as a treatment for excess weight.
The study was first submitted on Nov. 14, 2025, marking the formal start of the clinical path for this phase. The latest update was filed on Mar. 19, 2026, which signals that the protocol and status are current, while future primary and final completion dates will guide when investors can expect key data readouts.
For investors, this update supports the long-term obesity franchise story at Eli Lilly, which is already a major driver of LLY’s valuation. Positive outcomes could strengthen Lilly’s position against rival weight-loss drugs and support premium pricing, while any safety concerns or weak results could hurt sentiment across the broader obesity drug sector.
The study of retatrutide in obesity and overweight is currently active and updated, with more detailed information available on the ClinicalTrials.gov portal under identifier NCT07232719.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.